Wegovy a professionally prescribed drug for weight executives has acquired consideration for its viability in assisting people with accomplishing critical weight reduction On the off chance that youre ...

Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 ...

Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

The products are being advertised as more affordable alternatives to blockbuster weight-loss drugs. Here’s what doctors think ...

In this morning’s readout from Novo's phase 2 trial of monlunabant in 243 people with obesity and metabolic syndrome, it ...

The European Medicines Agency backed the use of Novo Nordisk's popular drug Wegovy to help ease heart failure in people with ...

A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...

Novo Nordisk’s obesity drug Wegovy is now recommended by EU regulatory authorities for obesity-related heart conditions.

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below market expectations.

The 20-year deal with Constellation Energy would kick-start the site of the nation's worst nuclear accident. Top-end German carmakers have joined expensive French handbags among the products hit by ...

Plus: The story behind the award-winning science that led to Ozempic, the next astronaut launch and why homework is good for ...

Cardinal Health on Friday agreed to acquire Integrated Oncology Network, an independent community oncology network, for $1.12 billion in cash.